Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Skating the Thin Ice of the Written Description Requirement

By Jack L. Chen
November 30, 2006

In recent years, cases such as Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956 (Fed. Cir. 2002) ('Enzo') and University of Rochester v. G.D. Searle and Co., Inc., 375 F.3d 1303 (Fed. Cir. 2004) ('Rochester') have fueled an ongoing debate over whether the first paragraph of 35 U.S.C. '112 includes a written description requirement, separate and distinct from enablement and best mode. According to Judge Randall Ray Rader, Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997) ('Eli Lilly') brought the written description requirement squarely to light. Rochester, 375 F.3d at 1307 (Circuit Judge Rader dissenting). This 'new' requirement creates 'enormous confusion,' not only for the courts, but also for patent drafters. Id. Because the requirement is in flux, patent practitioners should avoid overlooking the requirement or taking it too lightly.

In Rochester, a sharply divided Federal Circuit declined to rehear the district court's decision that invalidated a patent previously held by the University for failing to meet the separate written description requirement. Judge Alan David Lourie, in his concurring opinion, wrote that 'there is and always has been a separate written description requirement in the patent law.' Id. at 1305. Both Judges Richard Linn and Rader disagreed. First, '[r]eading into paragraph 1 of section 112 an independent written description requirement, divorced from enablement, sets up an inevitable clash between the claims and the written description as the focus of the scope of coverage. This is ill-advised.' Id. at 1307. Second, the Federal Circuit's issuance, withdrawal and re-issuance of the decision in the Enzo case indicated that a controversy existed over whether the written description requirement, as a separate and distinct requirement, is indeed valid. In Enzo, the Federal Circuit initially held that 'a deposit is not a substitute for a written description of the claimed invention.' Id. at 1308 (citation omitted). In so holding, the Federal Circuit applied the recently adopted requirement from Eli Lilly that a biotechnological invention must include a nucleotide-by-nucleotide recitation of its structure. Accordingly, the Enzo court invalidated the claims to a polypeptide detector, even though the patent described the polypeptides and three samples of the specifically claimed material were deposited at the American Type Culture Collection. Rochester, 375 F.3d at 1308. The Federal Circuit hastened to withdraw the initial Enzo decision following a firestorm of controversy and reversed the result. Id.

This premium content is locked for LJN Newsletters subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

CLE Shouldn't Be the Only Mandatory Training for Attorneys Image

Each stage of an attorney's career offers opportunities for a curriculum that addresses both the individual's and the firm's need to drive success.

A defendant in a patent infringement suit may, during discovery and prior to a <i>Markman</i> hearing, compel the plaintiff to produce claim charts, claim constructions, and element-by-element infringement analyses.